The WAIFW matrix represents the rate at which an infective of age X infects a susceptible of age Y (effective contact rate). Given the absence of empirical data, a simple matrix structure

was assumed and the elements of the matrices were mainly estimated from pre-vaccination seroprevalence or force of infection. Recently, a large population-based prospective survey of mixing patterns was conducted in eight European countries to provide empirical data for dynamic transmission models [35]. For our base case matrix, we used the overall empirical mixing patterns reported in Mossong et al. [35] and estimated the probability of transmission per contact required in order to fit Canadian age-specific force of infection [9] (see Appendix A). In the sensitivity analysis, we used (1) the WAIFW matrix reported in Brisson et al. [9] and (2) three RGFP966 in vivo effective contact

matrices based on the individual mixing patterns and force of infection from England and Wales, Finland, and Germany [35] and [36] (see Appendix A for matrix values). The Shingles Prevention Study (SPS) demonstrated that vaccine efficacy against zoster was significantly higher in adults aged 60–69 years compared to those 70 years and older UMI-77 [37]. It is thus likely that the probability of being boosted following exposure to VZV is also age-dependant. In our base case scenario, we reproduced the analysis described in Brisson et al. [8] assuming that the probability of being boosted is equal to the estimated age-specific zoster vaccine efficacy [37], [38] and [39]. Under this age-specific boosting assumption and using the same data and maximum likelihood function as Brisson et al. [8], exposure to varicella was estimated to protect against zoster for an average 24 years. In the sensitivity analysis, we explored two additional boosting assumptions:

(1) we used the previous Brisson et al. [8] estimates (100% chance of being boosted following VZV exposure and 20 years immunity) and (2) we assumed that exposure to varicella does not boost immunity against zoster. Age-specific rates Carnitine dehydrogenase of reactivation were estimated by fitting the model to Canadian age-specific incidence of zoster [9] using Least squares (see the Appendix A for model fit). Reactivation rates were estimated for each mixing matrix and VZV boosting scenario (see Table 1 and the appendix for parameter values). We assume that the rate of reactivation following breakthrough and natural varicella are identical. This assumption results in a lower overall rate of zoster in vaccinees given that many will not develop breakthrough varicella. Using methods similar to those described in Brisson et al.